10.2 Therapeutic Drug Monitoring in the ICU

Therapeutic Drug Monitoring in the ICU

Quick Answer: Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drugs at designated intervals to maintain a constant concentration in a patient's bloodstream. In the ICU, where pharmacokinetics are highly variable, TDM is vital for drugs with a narrow therapeutic index (like vancomycin, aminoglycosides, and phenytoin) to ensure efficacy and prevent toxicity.

Due to the unpredictable alterations in drug absorption, distribution, metabolism, and excretion (ADME) described in the previous section, standard dosing regimens often fail in critically ill patients. Therapeutic Drug Monitoring (TDM) utilizes measured drug concentrations, along with pharmacodynamic principles and patient-specific clinical data, to optimize pharmacotherapy.

Principles of TDM

TDM is not necessary for all medications. It is typically reserved for drugs that meet specific criteria:

1. Narrow Therapeutic Index: The difference between a therapeutic dose and a toxic dose is small.
2. Unpredictable Pharmacokinetics: The relationship between the administered dose and the resulting plasma concentration varies significantly between patients or within the same patient over time.
3. Clear Concentration-Effect Relationship: A defined correlation exists between plasma drug concentrations and clinical efficacy or toxicity.
4. Lack of Simple Clinical Endpoints: The drug's effect cannot be easily measured by routine clinical observation (e.g., it is easier to monitor blood pressure for an antihypertensive than to clinically assess the exact serum level of an antibiotic killing bacteria in the lungs).
5. Availability of an Assay: A fast, accurate, and cost-effective laboratory test must be available.

Timing of Sample Collection

The timing of blood draws relative to drug administration is critical for accurate TDM interpretation.

• Trough Concentration: Measured immediately before the next dose (typically within 30 minutes prior). Troughs evaluate drug clearance and are commonly used to monitor for toxicity and ensure minimum effective concentrations are maintained throughout the dosing interval.
• Peak Concentration: Measured after the drug is fully distributed (e.g., 30-60 minutes after an intravenous infusion completes). Peaks assess the maximum concentration achieved and correlate with efficacy for certain concentration-dependent drugs.
• Steady State: For drugs given repeatedly, concentrations reach a "steady state" when the rate of drug administration equals the rate of elimination. This typically occurs after 3 to 5 half-lives of the drug. Measuring levels before steady state can lead to premature dose adjustments, though early sampling is sometimes necessary in severe infections.

Common TDM Applications in the ICU

Vancomycin

Vancomycin is a glycopeptide antibiotic widely used for MRSA infections. It has a narrow therapeutic window and relies on renal clearance.

• Target: The primary PK/PD target for efficacy is the Area Under the Curve (AUC) over 24 hours divided by the Minimum Inhibitory Concentration (MIC), or AUC/MIC ratio (target typically 400-600 mg*hr/L for MRSA).
• Monitoring: Historically, trough-only monitoring (targeting 15-20 mg/L) was used as a surrogate for AUC. However, modern guidelines strongly recommend AUC-guided dosing (using Bayesian software or two-level pharmacokinetic equations) to optimize efficacy and reduce the risk of nephrotoxicity.

Aminoglycosides (e.g., Gentamicin, Tobramycin, Amikacin)

Aminoglycosides exhibit concentration-dependent bacterial killing (efficacy relates to peak concentration) and time-dependent toxicity (nephrotoxicity and ototoxicity relate to elevated trough concentrations).

• Extended-Interval Dosing (EID): The preferred strategy involves giving a large dose less frequently (e.g., every 24 hours). This maximizes the peak (optimizing killing) and allows for a prolonged drug-free interval, reducing accumulation and toxicity in the kidneys and ears.
• Monitoring: For EID, a random level is usually drawn (e.g., 6-14 hours after the dose) and plotted on a nomogram to determine the appropriate dosing interval.

Antiepileptic Drugs (AEDs)

Critically ill patients frequently require AEDs for seizures or status epilepticus.

• Phenytoin: Exhibits non-linear (Michaelis-Menten) pharmacokinetics, meaning small dose increases can lead to disproportionately large increases in serum levels. As discussed previously, phenytoin is highly protein-bound, so monitoring the free phenytoin level (target 1-2 mcg/mL) is often preferred over total levels in ICU patients with hypoalbuminemia.
• Valproic Acid and Levetiracetam: Also monitored to ensure therapeutic levels and avoid toxicity.

Digoxin

Used for rate control in atrial fibrillation or in heart failure. Digoxin has a long half-life and a narrow therapeutic index.

• Monitoring: Levels should be drawn at least 6-8 hours after a dose (to allow for full distribution into tissues) or as a trough prior to the next dose. Toxicity (arrhythmias, visual disturbances) correlates with elevated levels, particularly in the setting of hypokalemia, hypomagnesemia, or renal dysfunction.

Clinical Scenario

A 65-year-old female with MRSA bacteremia and acute kidney injury is started on intravenous vancomycin. The pharmacist uses a Bayesian dosing software to design a regimen.

TDM Process:

1. Initial Dosing: Based on her weight and estimated poor renal function, an initial dose and interval are chosen.
2. Sampling: A vancomycin peak level is drawn 1 hour after the end of the infusion, and a trough is drawn 30 minutes prior to the next dose.
3. Analysis: The pharmacist inputs the measured levels into the Bayesian software to estimate the patient's individual AUC24.
4. Adjustment: The estimated AUC24 is 320 mg*hr/L, which is below the target of 400-600. The pharmacist adjusts the dose upward to achieve the target AUC, ensuring effective bacterial eradication while carefully monitoring daily serum creatinine for signs of worsening nephrotoxicity.

TDM represents the intersection of pharmacology and personalized medicine, requiring meticulous attention to timing and physiological context.